One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Anti-Fungal Treatment Market

抗真菌治療市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2027年


[ 英語タイトル ] Anti-Fungal Treatment Market Research Report: Information by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), by Therapeutic Indication (Systemic, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), by Pathogen (Candid, Aspergillus, Cryptococcus, CoccidiodiesImmitis, Zygomycetes, Trichophyton), by End Users (Hospitals & Clinics, Dermatology Clinics) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027


Product Code : Market Research FutureHC00115186
Survey : Market Research Future
Publish On : September, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4450 / Question Form
Enterprise User USD6250 / Question Form
Pfizer Inc. (US), Astellas Pharma Ltd. (Japan), Novartis International AG (Switzerland), Sanofi S.A. (France), Merck KGaA (Germany), Bayer AG (Germany), Abbott Laboratories (US), Janssen Pharmaceuticals (US), Gilead Sciences, Inc. (US), and Cipla Inc. (India)

[Report Description]

Anti-Fungal Treatment Market Research Report—Forecast till 2027

Anti-Fungal Treatment Market Forecast
The Global anti-fungal treatment market is anticipated to register a healthy CAGR of 6.35% during the review period to surpass USD 25,764.67 million by 2027. Fungal are microorganisms that can remain alive in a wide cluster of conditions and can prompt different contaminations in the human body, going from shallow skin to foundational disease that enters the body through inward breath. These contaminations happen in the human body, generally because of high openness to unhygienic conditions of parasites or because of low safe frameworks.
The development of the worldwide antifungal treatment market is credited to the expanding episodes of fungal diseases. Different components like the expanding commonness of immunological sicknesses and the accessibility of a wide scope of items are driving the anti-fungal therapy market development. However, antifungal medicine can damage the kidney and liver and the allergic reactions caused due to antifungal medicines may hinder the market growth during the forecast period.
Market Segmentation
Anti-Fungal Treatment Market is categorized into Drug Class, therapeutic Indications, Pathogens, and end-user.
Based on drug class the global market has been classified into Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines, and Others.
By therapeutic Indications, the global antifungal treatment market is divided into Systemic, Aspergillosis, Geotrichosis, and others.
The Aspergillosis segment has further classified into Onychomycosis, Sinusitis, Keratitis, and Otomycosis.
In terms of Candidiasis, the global market has been segmented into Thrush, Mucosal Candida infections, Vaginal Candida infections, and Other Candida infections. The Cryptococcosis segment categorizes the market into Pulmonary cryptococcosis, Cryptococcal meningitis, and Others. Based on Prophylactic Use of Antifungals the global anti-fungal market has been divided into Cancer Patients, Transplantation and Abdominal Surgery Patients, Infants, and Coccidioidomycosis.
By Pathogens the global Anti-Fungal Treatment Market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, and Others
The End User segment has further been classified into Hospitals & Clinics, Dermatology Clinics, and Others.
Regional Analysis
Geographically, the global antifungal treatment market has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to dominate the market having the largest market share of 40.97% market share in 2019. The regional market is driven by the high incidences of antifungal diseases, growing research spending, and the adoption of advanced treatment in the region.
Europe is expected to drive the second largest market of global antifungal treatment during the review period. The regional market is fuelled by the availability of advanced treatment facilities, increasing government initiatives to promote research to find a cure to the growing patient pool, and growing healthcare expenditure.
The antifungal treatment market in Asia-Pacific is driven by the growing R&D funding in emerging countries such as China and India for the availability of basic treatments. Additionally, the increasing prevalence of fungal infections, the increasing availability of online pharmacies, and the growing number of healthcare professionals. The market for antifungal treatment is expected to grow at a steady rate in the Middle East & Africa due to the rising number of companies and subsidiaries in the region offering treatment options.
Major Players
The prominent market players of the global Anti-Fungal Market include Pfizer Inc. (US), Astellas Pharma Ltd. (Japan), Novartis International AG (Switzerland), Sanofi S.A. (France), Merck KGaA (Germany), Bayer AG (Germany), Abbott Laboratories (US), Janssen Pharmaceuticals (US), Gilead Sciences, Inc. (US), and Cipla Inc. (India).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS
4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES IN THE ANTI-FUNGAL TREATMENT
4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS OF TREATMENT
4.3.2 PRESENCE OF MISBRANDED AND SPURIOUS DRUGS
4.4 OPPORTUNITIES
4.4.1 DEVELOPMENT OF NEW DRUGS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING AND SALES
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 RIVALRY
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 IMPACT ON GLOBAL GROWTH
5.3.2 IMPACT ON MAJOR PLAYERS
5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS
6.1 OVERVIEW
6.2 AZOLES
6.3 ECHINOCANDNS
6.4 POLYENES
6.5 ALLYLAMINES
6.6 PYRIMIDINES
6.7 OTHERS
7 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATION
7.1 OVERVIEW
7.2 SYSTEMIC
7.3 CANDIDIASIS
7.4 CRYPTOCOCCOSIS
7.5 PROPHYLACTIC USE OF ANTIFUNGALS
7.6 COCCIDIOIDOMYCOSIS
8 GLOBAL ANTI-FUNGALTREATMENT MARKET, BY PATHOGEN
8.1 OVERVIEW
8.2 CANDIDA
8.3 ASPERGILLUS
8.4 CRYPTOCOCCUS
8.5 COCCIDIOIDES IMMITIS
8.6 ZYGOMYCETES
8.7 TRICHOPHYTON
8.8 OTHERS
9 GLOBAL ANTI-FUNGALTREATMENT MARKET, BY END USERS
9.1 OVERVIEW
9.2 HOSPITALS & CLINICS
9.3 DERMATOLOGY CLINICS
9.4 OTHERS
10 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICA
10.2.1 NORTH AMERICA
10.2.1.1 U.S.
10.2.1.2 CANADA
10.2.2 SOUTH AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REPUBLIC OF KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.5.1 ACQUISITIONS
11.5.2 COLLABORATIONS/AGREEMENTS
11.5.3 EXPANSIONS
12 COMPANY PROFILES
12.1 PFIZER
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ASTELLAS PHARMA LTD
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 NOVARTIS INTERNATIONAL AG
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 SWOT ANALYSIS
12.3.5 KEY STRATEGIES
12.4 SANOFI S.A.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 MERCK KGAA
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 BAYER AG
12.6.1 COMPANY OVERVIEWS
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 ABBOTT LABORATORIES
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 JANSSEN PHARMACEUTICALS
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 GILEAD SCIENCES, INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 CIPLA INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS
TABLE 2 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 3 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR AZOLES, BY REGION, 2017–2027 (USD MILLION)
TABLE 4 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR ECHINOCANDINS, BY REGION, 2017–2027 (USD MILLION)
TABLE 5 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR POLYENES, BY REGION, 2017–2027 (USD MILLION)
TABLE 6 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR ALLYLAMINES, BY REGION, 2017–2027 (USD MILLION)
TABLE 7 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR PYRIMIDINES, BY REGION, 2017–2027 (USD MILLION)
TABLE 8 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 9 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATION, 2017–2027 (USD MILLION)
TABLE 10 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY SYSTEMIC, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 11 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 12 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 13 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY CANDIDIASIS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 14 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 15 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY CRYPTOCOCCOSIS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 16 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 17 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY PROPHYLACTIC USE OF ANTIFUNGALS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 18 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 19 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY COCCIDIOIDOMYCOSIS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 20 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 21 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY CANDIDA, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 22 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY ASPERGILLUS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 23 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY CRYPTOCOCCUS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 24 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY COCCIDIOIDES IMMITIS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 25 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY ZYGOMYCETES, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 26 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY TRICHOPHYTON, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 27 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY OTHERS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 28 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 29 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY HOSPITALS & CLINICS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 30 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY DERMATOLOGY CLINICS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 31 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY OTHERS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION)
TABLE 32 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 33 AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 34 AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 35 AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 36 AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 37 AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 38 AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 39 AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 40 AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 41 AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 42 AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: ANT-FUNGAL TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 44 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 48 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 50 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 53 U.S.: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 54 U.S.: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 55 U.S.: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 56 U.S.: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 57 U.S.: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 58 U.S.: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 59 U.S: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 60 U.S: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 61 U.S: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 62 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 63 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 64 CANADA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 65 CANADA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 66 CANADA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 67 CANADA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 68 CANADA ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 69 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 70 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 71 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 72 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 73 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 74 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 75 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 76 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 77 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 78 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 79 SOUTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 80 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 81 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 82 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 83 EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 84 EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 85 EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 86 EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 87 EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 88 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 89 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 90 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 91 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 92 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 93 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 94 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 95 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 96 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 97 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 98 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 99 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 100 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 101 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 102 GERMANY: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 103 GERMANY: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 104 GERMANY: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 105 GERMANY: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 106 GERMANY: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 107 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 108 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 109 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 110 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 111 FRANCE: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 112 FRANCE: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 113 FRANCE: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 114 FRANCE: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 115 FRANCE: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 116 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 117 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 118 UK: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 119 UK: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 120 UK: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 121 UK: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 122 UK: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 123 UK: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 124 UK: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 125 UK: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 126 UK: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 127 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 128 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 129 ITALY: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 130 ITALY: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 131 ITALY: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 132 ITALY: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 133 ITALY: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 134 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 135 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 136 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 137 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 138 SPAIN: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 139 SPAIN: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 140 SPAIN: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 141 SPAIN: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 142 SPAIN: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 143 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 144 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 145 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 146 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 147 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 148 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 149 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 150 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 151 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 152 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 153 REST OF WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 154 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 155 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 156 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 157 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 158 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 159 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 160 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 161 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 162 EASTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 163 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 164 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 165 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 167 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 168 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 169 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 171 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 173 JAPAN: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 174 JAPAN: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 175 JAPAN: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 176 JAPAN: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 177 JAPAN: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 178 JAPAN: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 179 JAPAN: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 180 JAPAN: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 181 JAPAN: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 182 CHINA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 183 CHINA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 184 CHINA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 185 CHINA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 186 CHINA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 187 CHINA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 188 CHINA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 189 CHINA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 190 CHINA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 191 INDIA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 192 INDIA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 193 INDIA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 194 INDIA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 195 INDIA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 196 INDIA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 197 INDIA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 198 INDIA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 199 INDIA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 200 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 201 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 202 REUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 203 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 204 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 205 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 206 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 207 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 208 REPUBLIC OF KOREA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 209 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 210 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 211 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 212 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 213 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 214 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 215 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 216 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 217 AUSTRALIA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 218 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 219 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 220 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 221 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 222 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 223 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 224 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 225 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 226 REST OF ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 234 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 235 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 236 MIDDLE EAST & AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 237 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 238 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 239 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 240 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 241 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 242 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 243 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 244 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 245 MIDDLE EAST: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 246 AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION)
TABLE 247 AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATIONS, 2017–2027 (USD MILLION)
TABLE 248 AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR SYSTEMIC, BY TYPE, 2017–2027 (USD MILLION)
TABLE 249 AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 250 AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 251 AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR CRYPTOCOCCOSIS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 252 AFRICA: ANTI-FUNGAL TREATMENT MARKET, FOR PROPHYLACTIC USE OF ANTIFUNGALS, BY TYPE, 2017–2027 (USD MILLION)
TABLE 253 AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY PATHOGENS, 2017–2027 (USD MILLION)
TABLE 254 AFRICA: ANTI-FUNGAL TREATMENT MARKET, BY END USERS, 2017–2027 (USD MILLION)
TABLE 255 MOST ACTIVE PLAYER IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
TABLE 256 ACQUISITIONS
TABLE 257 COLLABORATIONS/AGREEMENTS
TABLE 258 EXPANSIONS
TABLE 259 PFIZER INC.: PRODUCTS/SERVICES OFFERED
TABLE 260 PFIZER INC.: KEY DEVELOPMENTS
TABLE 261 ASTELLAS PHARMA LTD: PRODUCTS/SERVICES OFFERED
TABLE 262 NOVARTIS INTERNATIONAL AG: PRODUCTS/SERVICES OFFERED
TABLE 263 SANOFI S.A.: PRODUCTS/SERVICES OFFERED
TABLE 264 MERCK KGAA: PRODUCTS/SERVICES OFFERED
TABLE 265 MERCK KGAA: KEY DEVELOPMENTS
TABLE 266 BAYER AG: PRODUCTS/SERVICES OFFERED
TABLE 267 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 268 JANSSEN PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED
TABLE 269 CIPLA INC.: PRODUCTS/SERVICES OFFERED
163

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL ANTI-FUNGAL TREATMENT MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS OVERVIEW
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 9 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, THERAPEUTIC INDICATION, 2019 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, PATHOGEN, 2019 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, END USERS, 2019 & 2027 (USD MILLION)
FIGURE 13 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION 2019 & 2027 (USD MILLION)
FIGURE 14 GLOBAL: ANTI-FUNGAL TREATMENT MARKET SHARE, BY REGION 2019 (%)
FIGURE 15 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET SHARE, BY COUNTRY 2019 (%)
FIGURE 16 WESTERN EUROPE: ANTI-FUNGAL TREATMENT MARKET SHARE, BY COUNTRY 2019 (%)
FIGURE 17 ASIA PACIFIC: ANTI-FUNGAL TREATMENT MARKET SHARE, BY REGION 2019 (%)
FIGURE 18 MAJOR MANUFACTURERS IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 21 GLOBAL ANTI-FUNGAL TREATMENT MARKET: COMPETITIVE LANDSCAPE
FIGURE 22 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 PFIZER INC.: SWOT ANALYSIS
FIGURE 24 ASTELLAS PHARMA LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 ASTELLAS PHARMA LTD: SWOT ANALYSIS
FIGURE 26 NOVARTIS INTERNATIONAL AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS
FIGURE 28 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SANOFI S.A.: SWOT ANALYSIS
FIGURE 30 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 MERCK KGAA: SWOT ANALYSIS
FIGURE 32 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 BAYER AG: SWOT ANALYSIS
FIGURE 34 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 ABBOTT LABORATORIES: SWOT ANALYSIS
FIGURE 36 JANSSEN PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 JANSSEN PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 38 GILEAD SCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 CIPLA INC.: SWOT ANALYSIS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+